518 related articles for article (PubMed ID: 15846258)
1. Enoxaparin versus unfractionated heparin as antithrombin therapy in patients receiving fibrinolysis for ST-elevation myocardial infarction. Design and rationale for the Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment-Thrombolysis In Myocardial Infarction study 25 (ExTRACT-TIMI 25).
Antman EM; Morrow DA; McCabe CH; Jiang F; White HD; Fox KA; Sharma D; Chew P; Braunwald E;
Am Heart J; 2005 Feb; 149(2):217-26. PubMed ID: 15846258
[No Abstract] [Full Text] [Related]
2. Effect of enoxaparin versus unfractionated heparin in diabetic patients with ST-elevation myocardial infarction in the Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment-Thrombolysis In Myocardial Infarction study 25 (ExTRACT-TIMI 25) trial.
Morrow DA; Antman EM; Murphy SA; Qin J; Ruda M; Guneri S; Jacob AJ; Budaj A; Braunwald E;
Am Heart J; 2007 Dec; 154(6):1078-84, 1084.e1. PubMed ID: 18035078
[TBL] [Abstract][Full Text] [Related]
3. Cost effectiveness of enoxaparin in acute ST-segment elevation myocardial infarction: the ExTRACT-TIMI 25 (Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment-Thrombolysis In Myocardial Infarction 25) study.
Marcoff L; Zhang Z; Zhang W; Ewen E; Jurkovitz C; Leguet P; Kolm P; Weintraub WS
J Am Coll Cardiol; 2009 Sep; 54(14):1271-9. PubMed ID: 19778669
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of enoxaparin versus unfractionated heparin in patients with ST-segment elevation myocardial infarction also treated with clopidogrel.
Sabatine MS; Morrow DA; Dalby A; Pfisterer M; Duris T; Lopez-Sendon J; Murphy SA; Gao R; Antman EM; Braunwald E;
J Am Coll Cardiol; 2007 Jun; 49(23):2256-63. PubMed ID: 17560290
[TBL] [Abstract][Full Text] [Related]
5. ExTRACT-TIMI 25 trial: clarifying the role of enoxaparin in patients with ST-elevation myocardial infarction receiving fibrinolysis.
Gabriel RS; White HD
Expert Rev Cardiovasc Ther; 2007 Sep; 5(5):851-7. PubMed ID: 17867915
[TBL] [Abstract][Full Text] [Related]
6. Percutaneous coronary intervention in patients receiving enoxaparin or unfractionated heparin after fibrinolytic therapy for ST-segment elevation myocardial infarction in the ExTRACT-TIMI 25 trial.
Gibson CM; Murphy SA; Montalescot G; Morrow DA; Ardissino D; Cohen M; Gulba DC; Kracoff OH; Lewis BS; Roguin N; Antman EM; Braunwald E;
J Am Coll Cardiol; 2007 Jun; 49(23):2238-46. PubMed ID: 17560287
[TBL] [Abstract][Full Text] [Related]
7. Enoxaparin is superior to unfractionated heparin in patients with ST elevation myocardial infarction undergoing fibrinolysis regardless of the choice of lytic: an ExTRACT-TIMI 25 analysis.
Giraldez RR; Nicolau JC; Corbalan R; Gurfinkel EP; Juarez U; Lopez-Sendon J; Parkhomenko A; Molhoek P; Mohanavelu S; Morrow DA; Antman EM
Eur Heart J; 2007 Jul; 28(13):1566-73. PubMed ID: 17562672
[TBL] [Abstract][Full Text] [Related]
8. Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction.
Antman EM; Morrow DA; McCabe CH; Murphy SA; Ruda M; Sadowski Z; Budaj A; López-Sendón JL; Guneri S; Jiang F; White HD; Fox KA; Braunwald E;
N Engl J Med; 2006 Apr; 354(14):1477-88. PubMed ID: 16537665
[TBL] [Abstract][Full Text] [Related]
9. [The treatment of acute coronary syndromes of the "non-ST elevation" type with enoxaparin: the TIMI 11B study. Thrombolysis in Myocardial Infarct].
Galli M
Ital Heart J Suppl; 2000 Apr; 1(4):575-6. PubMed ID: 10832148
[No Abstract] [Full Text] [Related]
10. One-year outcomes after a strategy using enoxaparin vs. unfractionated heparin in patients undergoing fibrinolysis for ST-segment elevation myocardial infarction: 1-year results of the ExTRACT-TIMI 25 trial.
Morrow DA; Antman EM; Fox KA; White HD; Giugliano R; Murphy SA; McCabe CH; Braunwald E;
Eur Heart J; 2010 Sep; 31(17):2097-102. PubMed ID: 20400762
[TBL] [Abstract][Full Text] [Related]
11. The impact of renal dysfunction on outcomes in the ExTRACT-TIMI 25 trial.
Fox KA; Antman EM; Montalescot G; Agewall S; SomaRaju B; Verheugt FW; Lopez-Sendon J; Hod H; Murphy SA; Braunwald E
J Am Coll Cardiol; 2007 Jun; 49(23):2249-55. PubMed ID: 17560289
[TBL] [Abstract][Full Text] [Related]
12. Enoxaparin is a cost-effective adjunct to fibrinolytic therapy for ST-elevation myocardial infarction in contemporary practice.
Menown I; Montalescot G; Pal N; Fidler C; Orme M; Gillard S
Adv Ther; 2010 Mar; 27(3):181-91. PubMed ID: 20422473
[TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of unfractionated heparin versus enoxaparin in patients who are obese and patients with severe renal impairment: analysis from the ESSENCE and TIMI 11B studies.
Spinler SA; Inverso SM; Cohen M; Goodman SG; Stringer KA; Antman EM;
Am Heart J; 2003 Jul; 146(1):33-41. PubMed ID: 12851605
[TBL] [Abstract][Full Text] [Related]
14. Global outcomes of ST-elevation myocardial infarction: comparisons of the Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment-Thrombolysis In Myocardial Infarction study 25 (ExTRACT-TIMI 25) registry and trial.
Steinberg BA; Moghbeli N; Buros J; Ruda M; Parkhomenko A; Raju BS; García-Castillo A; Janion M; Nicolau JC; Fox KA; Morrow DA; Gibson CM; Antman EM
Am Heart J; 2007 Jul; 154(1):54-61. PubMed ID: 17584551
[TBL] [Abstract][Full Text] [Related]
15. A strategy of using enoxaparin as adjunctive antithrombin therapy reduces death and recurrent myocardial infarction in patients who achieve early ST-segment resolution after fibrinolytic therapy: the ExTRACT-TIMI 25 ECG study.
Scirica BM; Morrow DA; Sadowski Z; Ruda M; Nicolau JC; Giugliano RP; Wiviott SD; Sabatine MS; Shui A; Antman EM; Braunwald E
Eur Heart J; 2007 Sep; 28(17):2070-6. PubMed ID: 17600039
[TBL] [Abstract][Full Text] [Related]
16. TIMI risk index and the benefit of enoxaparin in patients with ST-elevation myocardial infarction.
Ruff CT; Wiviott SD; Morrow DA; Mohanavelu S; Murphy SA; Antman EM; Braunwald E;
Am J Med; 2007 Nov; 120(11):993-8. PubMed ID: 17976428
[TBL] [Abstract][Full Text] [Related]
17. Design and rationale of Clopidogrel as Adjunctive Reperfusion Therapy-Thrombolysis in Myocardial Infarction (CLARITY-TIMI) 28 trial.
Sabatine MS; McCabe CH; Gibson CM; Cannon CP
Am Heart J; 2005 Feb; 149(2):227-33. PubMed ID: 15846259
[TBL] [Abstract][Full Text] [Related]
18. The greatest benefit of enoxaparin over unfractionated heparin in acute coronary syndromes is achieved in patients presenting with ST-segment changes: the Enoxaparin in Non-Q-Wave Coronary Events (ESSENCE) Electrocardiogram Core Laboratory Substudy.
Goodman SG; Bozovich GE; Tan M; Dos Santos A; Gurfinkel EP; Cohen M; Langer A;
Am Heart J; 2006 Apr; 151(4):791-7. PubMed ID: 16569535
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of enoxaparin in unselected patients with ST-segment elevation myocardial infarction.
Zeymer U; Gitt A; Jünger C; Bauer T; Heer T; Koeth O; Wienbergen H; Zahn R; Senges J
Thromb Haemost; 2008 Jan; 99(1):150-4. PubMed ID: 18217147
[TBL] [Abstract][Full Text] [Related]
20. Randomized comparison of enoxaparin with unfractionated heparin following fibrinolytic therapy for acute myocardial infarction.
Baird SH; Menown IB; Mcbride SJ; Trouton TG; Wilson C
Eur Heart J; 2002 Apr; 23(8):627-32. PubMed ID: 11969277
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
